Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMPHOTERICIN B vs ANCOBON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Aspergillosis,Blastomycosis,Candidiasis,Coccidioidomycosis,Cryptococcosis,Histoplasmosis,Mucormycosis,Sporotrichosis,Visceral leishmaniasis,Empiric therapy for febrile neutropenia,Meningitis (cryptococcal, coccidioidal)
Treatment of systemic fungal infections (e.g., candidiasis, cryptococcosis) in combination with amphotericin B,Off-label: Serious infections caused by susceptible fungi
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
Terminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (Cr Cl < 20 m L/min). Half-life correlates with creatinine clearance.
Primarily hepatic; exact enzymes not well characterized.
Deaminated to 5-fluorouracil in the body; further metabolized via same pathways as fluorouracil.
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
2-4% bound to plasma proteins (albumin).
4–5 L/kg (extensive tissue binding, especially in liver, spleen, and lungs).
0.6-0.9 L/kg, indicating distribution into total body water. Penetrates well into cerebrospinal fluid (50-100% of serum levels), aqueous humor, and peritoneal fluid.
IV: 100%; oral: <5%; topical: minimal systemic absorption.
Oral: 76-89% (well absorbed).
Acute kidney injury: consider dose reduction or switch to liposomal formulation. No specific GFR-based dose adjustments for conventional formulation; monitor renal function and electrolytes. For liposomal amphotericin B, no dosage adjustment required for renal impairment. Continuous renal replacement therapy: conventional amphotericin not recommended due to nephrotoxicity; liposomal preferred.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: 50-100 mg/kg/day divided every 12-24 hours; GFR <10 m L/min: 50-100 mg/kg/day every 24-48 hours; intermittent hemodialysis: 50-100 mg/kg/day with each dialysis session; peritoneal dialysis: 50-100 mg/kg/day every 48 hours.
No specific Child-Pugh based dose adjustments. Use caution in hepatic impairment; monitor liver function tests. Dose adjustment not typically required.
No specific pediatric dosing based on Child-Pugh; use with caution and monitor liver function, potential reduced clearance. No standard adjustment defined.
Conventional amphotericin B: 0.25-1.5 mg/kg/day IV; initial test dose 0.1 mg/kg. Liposomal amphotericin B: 3-5 mg/kg/day IV. For neonates: 1 mg/kg/day. Maximum daily dose: 1.5 mg/kg for conventional, 5 mg/kg for liposomal.
Weight-based: 50-150 mg/kg/day orally divided every 6 hours, or 50-150 mg/kg/day intravenously divided every 12 hours; neonates: 25-100 mg/kg/day intravenously divided every 12 hours.
Use with caution due to age-related renal function decline; monitor renal function and electrolyte levels carefully. Same dosing as adults; adjust for renal impairment if present. Lower doses may be considered based on clinical status.
Start at lower end of dosing range (50 mg/kg/day), adjust based on renal function; monitor for hematologic toxicity.
Amphotericin B should be used primarily for progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of fungal disease. It should be used under close medical supervision due to potential toxicity.
None.
Monitor renal function, electrolytes, and liver function; risk of nephrotoxicity, hypokalemia, hypomagnesemia, and infusion-related reactions; caution in patients with renal impairment and those receiving other nephrotoxic drugs.
Hematologic toxicity (leukopenia, thrombocytopenia); renal impairment requires dose adjustment; hepatotoxicity; monitoring of blood counts and renal function recommended.
Hypersensitivity to amphotericin B or any component of the formulation; unless the potential benefit outweighs the risk.
Hypersensitivity to flucytosine or any component.
Avoid excessive salt intake; monitor for hypokalemia and hypomagnesemia. No specific food restrictions but maintain adequate hydration.
May be taken with food to reduce gastrointestinal upset. No specific dietary restrictions. Avoid alcohol.
FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data suggest no increased risk of major malformations across all trimesters.
Flucytosine (ANCOBON) is teratogenic in animal studies, causing cleft palate, skeletal anomalies, and fetal resorption. Human data are limited; use in pregnancy only if clearly needed. Potential fetal risk in all trimesters. Contraindicated in first trimester unless life-threatening maternal infection.
Excreted in breast milk in low levels; M/P ratio not established. Consideration of benefits vs risks; caution in nursing infants due to potential for oral absorption and adverse effects.
Flucytosine is excreted into human breast milk; milk-to-plasma ratio approximately 1.0. Potential for serious adverse reactions in nursing infants; decision to discontinue nursing or drug depends on importance of drug to mother.
No specific dose adjustments recommended in pregnancy; standard dosing based on indication and patient weight. Pharmacokinetic changes in pregnancy (increased Vd, increased clearance) may theoretically require higher doses, but clinical data insufficient to recommend adjustment.
Pregnancy may alter pharmacokinetics due to increased renal clearance and expanded plasma volume. Dose adjustment may be necessary; maintain serum concentrations within therapeutic range (trough 20-50 mcg/m L). Reduce dose in renal impairment, which may occur in pregnancy. No specific pregnancy dose guidelines; use with caution and monitor levels.
Premedicate with acetaminophen, diphenhydramine, and hydrocortisone to reduce infusion-related reactions. Monitor serum potassium and magnesium closely due to renal wasting. Use normal saline bolus before infusion to reduce nephrotoxicity. Lipid formulations allow higher doses with less nephrotoxicity. Amphotericin B deoxycholate is reserved for severe, refractory cases.
Monitor for hepatotoxicity and bone marrow suppression; adjust dose in renal impairment (Cr Cl <50 m L/min requires dose interval extension). Obtain serum levels (desired peak 50-100 mcg/m L, trough <50 mcg/m L) to avoid toxicity. Use with caution in patients with pre-existing hematologic disorders or hepatic dysfunction. Synergistic with amphotericin B for cryptococcal meningitis; avoid concurrent use with nucleoside analogues (e.g., cytarabine) due to antagonism.
You may experience fever, chills, and nausea during infusion; these are common and can be managed with premedications.,Report any signs of kidney problems such as decreased urine output, swelling in legs, or fatigue.,Avoid potassium and magnesium supplements unless prescribed, as levels may fluctuate.,This medication can cause low blood pressure during infusion; rise slowly from sitting or lying down.,Complete the full course even if you feel better to prevent the infection from returning.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,May cause nausea and vomiting; taking with food can help.,Report any signs of liver problems (yellowing skin/eyes, dark urine, severe abdominal pain) or unusual bruising/bleeding immediately.,Avoid alcohol while on this medication.,Use effective contraception during treatment; notify your doctor if you become pregnant.,Regular blood tests are required to monitor blood counts and liver function.
"Efinaconazole, a triazole antifungal, inhibits fungal CYP450-dependent lanosterol 14α-demethylase, reducing ergosterol synthesis. Amphotericin B binds to ergosterol in fungal membranes, forming pores that cause cell death. Concomitant use may decrease Amphotericin B efficacy because efinaconazole depletes ergosterol, the target for Amphotericin B, potentially attenuating the polyene's antifungal activity, especially in systemic fungal infections."
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMPHOTERICIN B vs ANCOBON, answered by our medical review team.
AMPHOTERICIN B is a Antifungal that works by Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.. ANCOBON is a Antifungal that works by Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMPHOTERICIN B and ANCOBON depend on the specific clinical indication. These are both Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMPHOTERICIN B is: 0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.. The standard adult dose of ANCOBON is: 50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMPHOTERICIN B and ANCOBON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMPHOTERICIN B is classified as Category C. FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data sug. ANCOBON is classified as Category C. Flucytosine (ANCOBON) is teratogenic in animal studies, causing cleft palate, skeletal anomalies, and fetal resorption. Human data are limited; use in pregnancy only if clearly nee. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.